EAM
WVE icon

Exome Asset Management’s Wave Life Sciences WVE Stock Holding History

Exome Asset Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-421,488
Closed -$5.49M – 81
2025
Q4 		$7.17M Buy
+421,488
New +$4.28M 3.43% 7
2024
Q3 		– Sell
-488,135
Closed -$2.44M – 80
2024
Q2 		$2.44M Buy
+488,135
New +$2.78M 2.17% 22

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Exome Asset Management's WVE Position: Q1 2026 in Review

Exome Asset Management sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 421,488 shares — an estimated $5.49M sold.

Exome Asset Management first reported a position in WVE in Q2 2024 and held it in 2 quarters. The position peaked at $7.17M in Q4 2025. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Exome Asset Management reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 421,488 Wave Life Sciences shares in Q1 2026, an estimated $5.49M.
  • Exome Asset Management first reported a position in Wave Life Sciences in Q2 2024 and held it in 2 quarters.
  • Exome Asset Management's Wave Life Sciences position peaked at $7.17M in Q4 2025.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.